“Through the first nine months of the year, we delivered stable net revenue performance with contrasted results between the brands, while advancing our strategic priorities to drive our long-term growth,” said Michel Brousset, Waldencast (WALD) Founder and CEO. “In Q2 2025, our net revenue grew 5.6% year-over-year to $66.8 million and we delivered an Adjusted EBITDA Margin of 5.0%. In Q3 2025, our results reflected a contrasted performance across the portfolio. Performance at Obagi Medical continued to be supported by breakthrough innovation and the strengthening of the international business. Milk Makeup continued to grow consumption in the U.S. but faced a more challenging comparison against last year’s exceptionally successful launches, further impacted by softness in international markets.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast’s Obagi Medical to present new data at ASDS annual meeting
- Waldencast Enhances Financial Position with Trademark Sale and New Credit Facility
- Waldencast sells rights to the ‘Obagi’ trademark in Japan to Rohto for $82.5M
- Is WALD a Buy, Before Earnings?
- Obagi Medical launches Nu-Cil BioStim Scalp Serum